What Is Pharming Group N.V. (PHAR) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pharming Group N.V.'s intrinsic value is estimated at $8.91, suggesting the stock is overvalued at its current price of $13.31. With 9 out of 12 models flagging downside (-33.0% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: RCMH-DCF targets $19.25 (+44.6%), versus Dynamic NAV at $1.81 (-86.4%). This +131.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About PHAR?
12 of 13 models are currently active for PHAR. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates PHAR's intrinsic value at $2.64, implying -80.1% downside from the current price. See which stocks rank higher →
How Does PHAR Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PHAR ranks #402 by Quality of Company score. CirclFi's QOC score of 2.3/10 evaluates 32 fundamental signals. A score of 2.3 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Pharming Group N.V. competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is PHAR a Value Trap?
The Value Trap algorithm is not active for PHAR. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Pharming Group N.V.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Pharming Group N.V. is rated at 2.3/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.
The gap between the most bullish and bearish model spans +131.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PHAR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PHAR's 12 active models, average confidence is 20%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad